Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 23

Showing 23 citing articles:

Targeting the tumour vasculature: from vessel destruction to promotion
Sophie Guelfi, Kairbaan Hodivala‐Dilke, Gabriele Bergers
Nature reviews. Cancer (2024) Vol. 24, Iss. 10, pp. 655-675
Closed Access | Times Cited: 16
Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma
Md. Ataur Rahman, Meser M. Ali
Cancers (2024) Vol. 16, Iss. 17, pp. 2975-2975
Open Access | Times Cited: 7
PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
Zhaoqian He, Hua Chen, Liang Chen, et al.
ImmunoTargets and Therapy (2025) Vol. Volume 14, pp. 51-63
Open Access
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy
Peter J Matulich, Megan L. Burger
Cancer Cell (2025)
Closed Access
Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer
Chengdi Wang, Jingwei Li, Jingyao Chen, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
Yuhui Yang, Pingping Long, Ying Tuo, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
Junfeng Bu, Zihan Li, Die Hu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Targeted High‐Resolution 3D Imaging of Tumor Vasculatures at Different Stages Using Far‐Red AIE Nanoparticles Compatible with Tissue Clearing
Xiao‐Ting Gong, Xianyin Dai, Wei Cheng, et al.
Advanced Materials (2025)
Closed Access
Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy
Jing Jiao, You Wu, Shaoxian Wu, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Angiosarcoma: Role of Immunotherapy
Tom Wei‐Wu Chen
Current Treatment Options in Oncology (2025)
Closed Access
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023
Qifeng Chen, Xiongying Jiang, Minshan Chen, et al.
Annals of Surgery Open (2025) Vol. 6, Iss. 1, pp. e562-e562
Open Access
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
Yi Zhao, Ying He, Wei Wang, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 10, pp. 1347-1356
Closed Access | Times Cited: 4
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Douglas Hanahan, Olivier Michielin, Mikaël J. Pittet
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 4
Core-shell structured nanomembrane with sequential immune and vascular isolation effects followed by chondrogenic induction to promote stable stem cell-based subcutaneous cartilage regeneration in large animals
Erji Gao, Ziming Wang, Shaohua Zhao, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 154878-154878
Closed Access | Times Cited: 1
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma
Izuma Nakayama, Kohei Shitara
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 9, pp. 903-915
Closed Access | Times Cited: 1
Causal associations of tea consumption on risk of pancreatic adenocarcinoma and the mediating role of vascular endothelial growth factor D levels
Yonghao Ouyang, Beini Zhou, Lihua Chu, et al.
British Journal Of Nutrition (2024), pp. 1-10
Open Access | Times Cited: 1
Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report
Haoyue Qin, Huan Yan, Xing Zhang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer
Behshid Ghadrdoost Nakhchi, Ramoji Kosuru, Magdalena Chrzanowska‐Wodnicka
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 9853-9853
Open Access
Medikamentöse Tumortherapie jenseits der Zulassung
Valentin Steinacker, Urs Müller‐Richter, Stefan Hartmann, et al.
Die MKG-Chirurgie (2024) Vol. 17, Iss. 4, pp. 258-266
Closed Access
Role of kiwifruit in the inhibition of carcinogenesis: Proof-of-concept from cell culture studies and xenografted mice
Mirna Azalea Romero, Sundas Fayyaz, Mahrukh Tariq, et al.
Postępy Higieny i Medycyny Doświadczalnej (2024) Vol. 78, Iss. 1, pp. 125-130
Open Access
Manganese improves anti-PD-L1 immunotherapy via eliciting type I interferon signaling in melanoma
Xiao-Xin Zhang, Jianhua Deng, Renjie Wu, et al.
Investigational New Drugs (2024)
Closed Access
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study
Li Hu, Zhoutian Yang, Zhenyun Yang, et al.
Hepatology International (2024)
Closed Access
Inhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment
Wanting Hou, Chaoxin Xiao, Ruihan Zhou, et al.
Theranostics (2024) Vol. 15, Iss. 1, pp. 258-276
Closed Access
Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
Zhonghua Zhao, Xiongying Jiang, Shiping Wen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors
Yong Zhou, Zhengcheng Liu, Ao Yu, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 813-829
Open Access
Page 1

Scroll to top